Raredr

Emerging Therapies for Duchenne Muscular Dystrophy

Jean Mah, MD
Published Online: Friday, Nov 04, 2016



Jean L Mah, MD,  Associate Professor of Pediatric Neurology at Alberta Children's Hospital talks about the history, pathogenesis, treatment, and standard of care for boys with Duchenne muscular dystrophy. This symposium was filmed at the Child Neurology Society annual meeting in Vancouver, Canada on October 28, 2016.
 
Some of the therapies/targets discussed by Dr Mah include eteplirsen, SRP-053, NS-065, SRP-4045, DS-514b, ataluren, follistatin, AAV microdystrophin, GALGT2, myoblast transplant, cardiac stell cells, iPS stem cells, ezutrmid, domoagrozumab, BMS-986089, FG-3019, CAT-1004, givinostat, vamorolone, rimiporide, ARM210, nebivolol, spriromolactone, eplerenone, Ramipril, carvedilol, and idebenone. 
 
For more information about some of the clinical trials and therapies discussed by Dr Mah, visit jettfoundation.org.

Rare Disease Report would like to thank Dr Mah and the Jett Foundation for their support in allowing us to film this symposium and to share it with the rare disease community.

Latest Articles
Positive initial results from a Phase 1A clinical trial evaluating setmelanotide (RM-492) for the treatment of rare genetic disorders of obesity were reported.
He’s a patient, an educator, and an advocate. Huntington's Disease patient and Bellingham researcher Jeff Carroll is a triple threat.
Dr Gavin Rumbaugh, PhD of Scripps Florida Research Institute was awarded an NIMH-funded grant for the therapeutic development of Syngap1.
Cooper sits down with RDR to talk about A4250, why it’s so important to children with PFIC, and just how Albireo prioritizes treatment for rare diseases.
$vacMongoViewPlus$ $vAR$